Gilead Sciences, Inc. (GILD) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - General
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Gilead (GILD) Q4 2025: Yes2Go Set for $800M Surge, Pivots HIV Prevention Growth Trajectory
June 15, 2026
-
Gilead (GILD) Q1 2026: Yes2Go Guidance Raised to $1B as HIV and Oncology Pipeline Accelerates
May 08, 2026
-
Gilead (GILD) Q3 2025: Yes2Go Hits 75% Coverage, Setting Up 2026 HIV Prevention Ramp
October 30, 2025
-
Gilead (GILD) Q2 2025: HIV Base Business Up 4% as Yes2Go Launch Drives Prevention Market Expansion
August 08, 2025
-
Gilead (GILD) Q1 2025: HIV Base Grows 6% as Lenacapavir Launch Nears, Offsetting Oncology and Cell Therapy Drag
July 01, 2025